

Christian F Singer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7800402/publications.pdf>

Version: 2024-02-01

174
papers

9,022
citations

81743

39
h-index

48187

88
g-index

181
all docs

181
docs citations

181
times ranked

12711
citing authors

#	ARTICLE	IF	CITATIONS
1	Breast and Prostate Cancer Risks for Male <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variant Carriers Using Polygenic Risk Scores. <i>Journal of the National Cancer Institute</i> , 2022, 114, 109-122.	3.0	19
2	A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 106-115.	3.2	18
3	Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response. <i>Clinical Cancer Research</i> , 2022, 28, 697-707.	3.2	17
4	Updated Austrian treatment algorithm in HER2+ metastatic breast cancer. <i>Wiener Klinische Wochenschrift</i> , 2022, 134, 63-72.	1.0	1
5	Cancer Risks Associated With <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variants. <i>Journal of Clinical Oncology</i> , 2022, 40, 1529-1541.	0.8	90
6	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. <i>European Journal of Human Genetics</i> , 2022, 30, 349-362.	1.4	23
7	Contraceptive use and the risk of ovarian cancer among women with a <i>BRCA1</i> or <i>BRCA2</i> mutation. <i>Gynecologic Oncology</i> , 2022, 164, 514-521.	0.6	8
8	Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). <i>Journal of Clinical Oncology</i> , 2022, 40, 282-293.	0.8	88
9	Abstract P1-16-03: Response pattern to chemotherapy in metastatic breast cancer (MBC): Real-word data from the Austrian AGMT_MBC-Registry. <i>Cancer Research</i> , 2022, 82, P1-16-03-P1-16-03.	0.4	0
10	Abstract GS1-07: Adjuvant palbociclib in HR+/HER2- early breast cancer: Final results from 5,760 patients in the randomized phase III PALLAS trial. <i>Cancer Research</i> , 2022, 82, GS1-07-GS1-07.	0.4	0
11	Abstract P1-02-07: Accuracy and predictive value of resection margin assessment by intraoperative frozen section after neoadjuvant therapy: An analysis of the ABCSC 24 and 34 trials. <i>Cancer Research</i> , 2022, 82, P1-02-07-P1-02-07.	0.4	0
12	Abstract P1-15-01: Effect of concomitant statin treatment in postmenopausal patients with hormone-receptor positive early-stage breast cancer receiving adjuvant denosumab or placebo: A <i>post-hoc</i> analysis of ABCSG-18. <i>Cancer Research</i> , 2022, 82, P1-15-01-P1-15-01.	0.4	0
13	Abstract P1-02-06: Prediction of Prosigna® breast cancer intrinsic subtype by immunohistochemical ER, PR and Ki67 expression. <i>Cancer Research</i> , 2022, 82, P1-02-06-P1-02-06.	0.4	0
14	Abstract P1-21-08: Brain metastases (BM) from breast cancer: Real-word data from the Austrian AGMT_MBC-registry. <i>Cancer Research</i> , 2022, 82, P1-21-08-P1-21-08.	0.4	1
15	Abstract P4-12-10: Cancer worry among healthy <i>BRCA</i> mutation carriers in Austria: A pilot study. <i>Cancer Research</i> , 2022, 82, P4-12-10-P4-12-10.	0.4	0
16	Abstract P5-18-02: Final findings from the CONTROL trial of diarrheal prophylaxis or neratinib dose escalation on neratinib-associated diarrhea and tolerability in patients with HER2+ early-stage breast cancer. <i>Cancer Research</i> , 2022, 82, P5-18-02-P5-18-02.	0.4	1
17	Altered Expression of RB and pRB in Tissue Arrays of Primary Breast Cancers and Matched Axillary Lymph Node Metastases. <i>Breast Journal</i> , 2022, 2022, 1-6.	0.4	0
18	Decision Theory versus Conventional Statistics for Personalized Therapy of Breast Cancer. <i>Journal of Personalized Medicine</i> , 2022, 12, 570.	1.1	1

#	ARTICLE	IF	CITATIONS
19	Bilateral Oophorectomy and the Risk of Breast Cancer in <i>BRCA1</i> Mutation Carriers: A Reappraisal. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1351-1358.	1.1	3
20	A phase 3 study to determine the breast cancer risk reducing effect of denosumab in women carrying a germline <i>BRCA1</i> mutation (BRCA-P Study).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS10616-TPS10616.	0.8	2
21	Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2 ⁻) advanced breast cancer (ABC): Biomarker (BM) analyses by next-generation sequencing (NGS) from the SOLAR-1 study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 1006-1006.	0.8	4
22	Long-term outcomes of adjuvant denosumab in breast cancer: Fracture reduction and survival results from 3,425 patients in the randomised, double-blind, placebo-controlled ABCSG-18 trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 507-507.	0.8	15
23	Nonsurgical Prevention Strategies in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Breast Care</i> , 2021, 16, 144-148.	0.8	19
24	Radiotherapy-Induced Fatigue in Breast Cancer Patients. <i>Breast Care</i> , 2021, 16, 236-242.	0.8	9
25	Patient satisfaction after breast cancer surgery. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 6-13.	1.0	11
26	Breast cancer risk after age 60 among <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 515-523.	1.1	5
27	Decision theory for precision therapy of breast cancer. <i>Scientific Reports</i> , 2021, 11, 4233.	1.6	3
28	Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34. <i>British Journal of Cancer</i> , 2021, 124, 1795-1802.	2.9	3
29	Extrasosseous osteoblastoma: A rare cause of breast mass in a prepubertal girl. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e04094.	0.2	0
30	Tissue Sodium Concentration Quantification at 7.0-T MRI as an Early Marker for Chemotherapy Response in Breast Cancer: A Feasibility Study. <i>Radiology</i> , 2021, 299, 63-72.	3.6	7
31	The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous <i>BRCA1</i> or <i>BRCA2</i> pathogenic variant. <i>Genetics in Medicine</i> , 2021, 23, 1726-1737.	1.1	16
32	Reliability of Tumor Testing Compared to Germline Testing for Detecting <i>BRCA1</i> and <i>BRCA2</i> Mutations in Patients with Epithelial Ovarian Cancer. <i>Journal of Personalized Medicine</i> , 2021, 11, 593.	1.1	11
33	Invasive lobular carcinoma: clinicopathological features and subtypes. <i>Journal of International Medical Research</i> , 2021, 49, 030006052110170.	0.4	4
34	Correlation between preoperative radiological and postoperative pathological tumor size in patients with HER2+ breast cancer after neoadjuvant chemotherapy plus trastuzumab and pertuzumab. <i>Clinical Breast Cancer</i> , 2021, . .	1.1	1
35	Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer. <i>New England Journal of Medicine</i> , 2021, 385, 395-405.	13.9	82
36	Abstract 878: Contraceptive use and ovarian cancer risk in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers: A prospective cohort study. <i>Cancer Research</i> , 2021, 81, 878-878.	0.4	1

#	ARTICLE	IF	CITATIONS
37	Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 225, 51.e1-51.e17.	0.7	34
38	The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptor-Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSG Trial 8. <i>Clinical Cancer Research</i> , 2021, 27, 5931-5938.	3.2	1
39	Weight Gain and the Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 2038-2043.	1.1	6
40	Cancer Spectrum, Family History of Cancer and Overall Survival in Men with Germline BRCA1 or BRCA2 Mutations. <i>Journal of Personalized Medicine</i> , 2021, 11, 917.	1.1	3
41	Tailored axillary surgery in patients with clinically node-positive breast cancer: Pre-planned feasibility substudy of TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBC 101). <i>Breast</i> , 2021, 60, 98-110.	0.9	28
42	Expression of COX-2, p16, and Ki67 in the range from normal breast tissue to breast cancer. <i>Neoplasma</i> , 2021, 68, 342-351.	0.7	7
43	Genetic Testing in Breast Cancer: New Standards of Care. <i>Breast Care</i> , 2021, 16, 193-195.	0.8	0
44	Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. <i>Cancer Research</i> , 2020, 80, 624-638.	0.4	39
45	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. <i>Nature Genetics</i> , 2020, 52, 56-73.	9.4	120
46	Decrease in gynecological cancer diagnoses during the COVID-19 pandemic: an Austrian perspective. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1667-1671.	1.2	33
47	Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation. <i>Gynecologic Oncology</i> , 2020, 159, 820-826.	0.6	10
48	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. <i>Genetics in Medicine</i> , 2020, 22, 1653-1666.	1.1	82
49	Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 44.	2.3	5
50	Microarray Normalization Revisited for Reproducible Breast Cancer Biomarkers. <i>BioMed Research International</i> , 2020, 2020, 1-27.	0.9	3
51	Homologous recombination deficiency: New biomarkers in innovative treatments. <i>Memo - Magazine of European Medical Oncology</i> , 2020, 13, 357-358.	0.3	0
52	Receptor Discordance of Metastatic Breast Cancer Depending on the Molecular Subtype. <i>Breast Care</i> , 2020, 15, 648-654.	0.8	3
53	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. <i>Nature Genetics</i> , 2020, 52, 572-581.	9.4	265
54	Factors influencing agreement of breast cancer luminal molecular subtype by Ki67 labeling index between core needle biopsy and surgical resection specimens. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 477, 545-555.	1.4	5

#	ARTICLE	IF	CITATIONS
55	The EndoPredict score predicts response to neoadjuvant chemotherapy and neoadjuvant endocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial. <i>European Journal of Cancer</i> , 2020, 134, 99-106.	1.3	29
56	Complication rates among women undergoing preventive mastectomy: An Austrian registry. <i>Breast Journal</i> , 2020, 26, 1639-1644.	0.4	4
57	Predictive Value of Molecular Subtypes in Premenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the ABCSG Trial 5. <i>Clinical Cancer Research</i> , 2020, 26, 5682-5688.	3.2	4
58	Characterization of the Cancer Spectrum in Men With Germline <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variants. <i>JAMA Oncology</i> , 2020, 6, 1218.	3.4	48
59	Transcriptome-wide association study of breast cancer risk by estrogen receptor status. <i>Genetic Epidemiology</i> , 2020, 44, 442-468.	0.6	32
60	Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: Results from The <i>BRCA1</i> and <i>BRCA2</i> Cohort Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 368-378.	1.1	24
61	Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. <i>Breast Cancer Research</i> , 2020, 22, 8.	2.2	41
62	Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34). <i>European Journal of Cancer</i> , 2020, 132, 43-52.	1.3	24
63	Non-surgical prevention strategies in women with hereditary breast and ovarian cancer syndromes. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2020, 41, .	0.3	5
64	Association of Cytokeratin 5 and Claudin 3 expression with <i>BRCA1</i> and <i>BRCA2</i> germline mutations in women with early breast cancer. <i>BMC Cancer</i> , 2019, 19, 695.	1.1	4
65	Shared heritability and functional enrichment across six solid cancers. <i>Nature Communications</i> , 2019, 10, 431.	5.8	88
66	A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB). <i>Clinical Cancer Research</i> , 2019, 25, 2975-2987.	3.2	76
67	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. <i>British Journal of Cancer</i> , 2019, 121, 180-192.	2.9	19
68	Patient-derived cell line models revealed therapeutic targets and molecular mechanisms underlying disease progression of high grade serous ovarian cancer. <i>Cancer Letters</i> , 2019, 459, 1-12.	3.2	16
69	Prediction of Distant Recurrence Using EndoPredict Among Women with ER+, HER2 ⁺ Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only. <i>Clinical Cancer Research</i> , 2019, 25, 3865-3872.	3.2	54
70	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. <i>Nature Communications</i> , 2019, 10, 1741.	5.8	90
71	Contralateral prophylactic mastectomy in women with breast cancer without a family history or genetic predisposition. <i>Wiener Klinische Wochenschrift</i> , 2019, 131, 233-236.	1.0	2
72	7T CEST MRI: A potential imaging tool for the assessment of tumor grade and cell proliferation in breast cancer. <i>Magnetic Resonance Imaging</i> , 2019, 59, 77-87.	1.0	23

#	ARTICLE	IF	CITATIONS
73	Association between family history, mutation locations, and prevalence of <i>BRCA1</i> or <i>BRCA2</i> mutations in ovarian cancer patients. <i>Cancer Medicine</i> , 2019, 8, 1875-1881.	1.3	17
74	Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSC-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , 2019, 20, 339-351.	5.1	167
75	Oophorectomy and risk of contralateral breast cancer among <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 443-449.	1.1	12
76	<i>PIK3CA</i> Amplification Associates with Aggressive Phenotype but Not Markers of AKT-MTOR Signaling in Endometrial Carcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 334-345.	3.2	17
77	Genetic counselling and testing of susceptibility genes for therapeutic decision-making in breast cancer: an European consensus statement and expert recommendations. <i>European Journal of Cancer</i> , 2019, 106, 54-60.	1.3	25
78	Height and Body Mass Index as Modifiers of Breast Cancer Risk in <i>BRCA1</i> / <i>BRCA2</i> Mutation Carriers: A Mendelian Randomization Study. <i>Journal of the National Cancer Institute</i> , 2019, 111, 350-364.	3.0	30
79	CDK4/6 inhibition in low burden and extensive metastatic breast cancer: summary of an ESMO Open Cancer Horizons pro and con discussion. <i>ESMO Open</i> , 2019, 4, e000565.	2.0	8
80	IgG based immunome analyses of breast cancer patients reveal underlying signaling pathways. <i>Oncotarget</i> , 2019, 10, 3491-3505.	0.8	7
81	Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among <i>BRCA1</i> Mutation Carriers. <i>JAMA Oncology</i> , 2018, 4, 1059.	3.4	121
82	Mutational spectrum in a worldwide study of 29,700 families with <i>BRCA1</i> or <i>BRCA2</i> mutations. <i>Human Mutation</i> , 2018, 39, 593-620.	1.1	224
83	The association between smoking and cancer incidence in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. <i>International Journal of Cancer</i> , 2018, 142, 2263-2272.	2.3	20
84	Prospective evaluation of body size and breast cancer risk among <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. <i>International Journal of Epidemiology</i> , 2018, 47, 987-997.	0.9	11
85	Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial). <i>BMC Cancer</i> , 2018, 18, 1074.	1.1	12
86	Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a <i>BRCA1</i> and <i>BRCA2</i> Mutation Carrier Cohort Study. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky023.	1.4	33
87	Age-specific ovarian cancer risks among women with a <i>BRCA1</i> or <i>BRCA2</i> mutation. <i>Gynecologic Oncology</i> , 2018, 150, 85-91.	0.6	65
88	Age at first full-term birth and breast cancer risk in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 421-426.	1.1	10
89	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. <i>Cancer Research</i> , 2018, 78, 5419-5430.	0.4	54
90	Improving comprehension of genetic counseling for hereditary breast and ovarian cancer clients with a visual tool. <i>PLoS ONE</i> , 2018, 13, e0200559.	1.1	11

#	ARTICLE	IF	CITATIONS
91	Co-expressed genes enhance precision of receptor status identification in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 313-326.	1.1	7
92	Differential Claudin 3 and EGFR Expression Predicts BRCA1 Mutation in Triple-Negative Breast Cancer. <i>Cancer Investigation</i> , 2018, 36, 378-388.	0.6	8
93	Adjuvant denosumab in early breast cancer: Disease-free survival analysis of 3,425 postmenopausal patients in the ABCSG-18 trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 500-500.	0.8	23
94	Efficient leukocyte depletion by a novel microfluidic platform enables the molecular detection and characterization of circulating tumor cells. <i>Oncotarget</i> , 2018, 9, 812-823.	0.8	35
95	Estrogen abrogates zoledronic acid induced gene expression signature in endocrine sensitive tumor cell lines in vitro.. <i>Journal of Clinical Oncology</i> , 2018, 36, e12570-e12570.	0.8	0
96	Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 3676-3683.	3.2	29
97	The effect of obesity on pathological complete response and survival in breast cancer patients receiving uncapped doses of neoadjuvant anthracycline-taxane-based chemotherapy. <i>Breast</i> , 2017, 33, 153-158.	0.9	25
98	Therapeutic Strategies in Triple-Negative Breast Cancer. <i>Breast Care</i> , 2017, 12, 6-7.	0.8	4
99	AGO Austria recommendation on screening and diagnosis of Lynch syndrome (LS). <i>Archives of Gynecology and Obstetrics</i> , 2017, 296, 123-127.	0.8	8
100	Risks of Breast, Ovarian, and Contralateral Breast Cancer for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 2402.	3.8	1,898
101	Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients. <i>Seminars in Oncology</i> , 2017, 44, 187-197.	0.8	76
102	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. <i>Nature Genetics</i> , 2017, 49, 1767-1778.	9.4	289
103	Identification and management of familial breast cancer in Austria. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2017, 32, .	0.3	2
104	Adverse Events of Trastuzumab Emtansine (T-DM1) in the Treatment of HER2-Positive Breast Cancer Patients. <i>Breast Care</i> , 2017, 12, 401-408.	0.8	28
105	Influence of Orally Administered Probiotic Lactobacillus Strains on Vaginal Microbiota in Women with Breast Cancer during Chemotherapy: A Randomized Placebo-Controlled Double-Blinded Pilot Study. <i>Breast Care</i> , 2017, 12, 335-339.	0.8	30
106	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 117-134.	1.1	18
107	Can we prevent BRCA1-associated breast cancer by RANKL inhibition?. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 11-16.	1.1	27
108	Bilateral Oophorectomy and Breast Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	160

#	ARTICLE	IF	CITATIONS
109	Adverse Mucocutaneous Reaction to Pertuzumab in a Patient with HER2-Positive Metastatic Breast Cancer. <i>Breast Journal</i> , 2017, 23, 352-353.	0.4	4
110	Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers. <i>PLoS ONE</i> , 2017, 12, e0189641.	1.1	8
111	Estradiol impairs the antiproliferative and proapoptotic effect of Zoledronic acid in hormone sensitive breast cancer cells in vitro. <i>PLoS ONE</i> , 2017, 12, e0185566.	1.1	7
112	PTEN expression as a predictor for the response to trastuzumab-based therapy in Her-2 overexpressing metastatic breast cancer. <i>PLoS ONE</i> , 2017, 12, e0172911.	1.1	12
113	Multi-level suppression of receptor-PI3K-mTORC1 by fatty acid synthase inhibitors is crucial for their efficacy against ovarian cancer cells. <i>Oncotarget</i> , 2017, 8, 11600-11613.	0.8	43
114	Gene expression information improves reliability of receptor status in breast cancer patients. <i>Oncotarget</i> , 2017, 8, 77341-77359.	0.8	7
115	Changes of Socio-demographic data of clients seeking genetic counseling for hereditary breast and ovarian cancer due to the "Angelina Jolie Effect". <i>BMC Cancer</i> , 2016, 16, 436.	1.1	49
116	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. <i>PLoS ONE</i> , 2016, 11, e0158801.	1.1	10
117	HER Specific TKIs Exert Their Antineoplastic Effects on Breast Cancer Cell Lines through the Involvement of STAT5 and JNK. <i>PLoS ONE</i> , 2016, 11, e0146311.	1.1	21
118	Cadherin-11 expression is upregulated in invasive human breast cancer. <i>Oncology Letters</i> , 2016, 12, 4393-4398.	0.8	21
119	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. <i>Breast Cancer Research</i> , 2016, 18, 64.	2.2	31
120	Profiling of Cross-Functional Peptidases Regulated Circulating Peptides in BRCA1 Mutant Breast Cancer. <i>Journal of Proteome Research</i> , 2016, 15, 1534-1545.	1.8	9
121	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. <i>Breast Cancer Research</i> , 2016, 18, 15.	2.2	88
122	An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 319-327.	1.1	26
123	ESR1 -Amplification-Associated Estrogen Receptor \pm Activity in Breast Cancer. <i>Trends in Endocrinology and Metabolism</i> , 2016, 27, 751-752.	3.1	8
124	Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. <i>Breast Cancer Research</i> , 2016, 18, 112.	2.2	42
125	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. <i>Nature Communications</i> , 2016, 7, 11375.	5.8	93
126	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. <i>Nature Communications</i> , 2016, 7, 12675.	5.8	78

#	ARTICLE	IF	CITATIONS
127	Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 1888.	3.8	79
128	RANKL/RANK control Brca1 mutation-driven mammary tumors. <i>Cell Research</i> , 2016, 26, 761-774.	5.7	128
129	Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a caseâ€“control study. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 365-373.	1.1	55
130	Quantitative Sodium MR Imaging at 7 T: Initial Results and Comparison with Diffusion-weighted Imaging in Patients with Breast Tumors. <i>Radiology</i> , 2016, 280, 39-48.	3.6	69
131	Combined genetic and splicing analysis of BRCA1 c.[594-2A>C; 641A>G] highlights the relevance of naturally occurring in-frame transcripts for developing disease gene variant classification algorithms. <i>Human Molecular Genetics</i> , 2016, 25, 2256-2268.	1.4	106
132	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. <i>Nature Genetics</i> , 2016, 48, 374-386.	9.4	125
133	PANTHER: Prospective randomized phase III trial of tailored and dose-dense versus standard tri-weekly adjuvant chemotherapy for high-risk breast cancer in the modern era of endocrine and anti-HER2 therapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, 1002-1002.	0.8	2
134	Plasma osteoprotegerin and breast cancer risk in BRCA1 and BRCA2 mutation carriers. <i>Oncotarget</i> , 2016, 7, 86687-86694.	0.8	28
135	Evaluation of pretherapeutic Ki67 as predictive marker for response to neoadjuvant chemotherapy in patients with primary breast cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, e12500-e12500.	0.8	0
136	The impact on socio-demographic characteristics of clients seeking genetic counseling for hereditary breast and ovarian cancer due to the outing of Angelina Jolie.. <i>Journal of Clinical Oncology</i> , 2016, 34, e13119-e13119.	0.8	0
137	Circulating tumor cells as an early detection tool for BRCA positive women?. <i>Journal of Clinical Oncology</i> , 2016, 34, e13025-e13025.	0.8	0
138	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2015, 17, 61.	2.2	26
139	Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers. <i>PLoS ONE</i> , 2015, 10, e0120020.	1.1	34
140	Prognostic Relevance of Pretherapeutic Gamma-Glutamyltransferase in Patients with Primary Metastatic Breast Cancer. <i>PLoS ONE</i> , 2015, 10, e0125317.	1.1	40
141	Adjuvant denosumab in breast cancer (ABCSC-18): a multicentre, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2015, 386, 433-443.	6.3	444
142	Prophylactic long-acting granulocyte-colony stimulating factors (G-CSF) in gynecologic malignancies: an oncologic expert statement. <i>Wiener Medizinische Wochenschrift</i> , 2015, 165, 387-394.	0.5	5
143	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. <i>Nature Genetics</i> , 2015, 47, 164-171.	9.4	221
144	Postoperative CMF Does Not Ameliorate Poor Outcomes in Women With Residual Invasive Breast Cancer After Neoadjuvant Epirubicin/Docetaxel Chemotherapy. <i>Clinical Breast Cancer</i> , 2015, 15, 505-511.	1.1	4

#	ARTICLE	IF	CITATIONS
145	The pre-analytical processing of blood samples for detecting biomarkers on protein microarrays. <i>Journal of Immunological Methods</i> , 2015, 418, 39-51.	0.6	14
146	Association of Type and Location of <i>BRCA1</i> and <i>BRCA2</i> Mutations With Risk of Breast and Ovarian Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1347.	3.8	390
147	Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 308-316.	1.1	22
148	Residual breast tissue after mastectomy in non high risk and BRCA mutated patients.. <i>Journal of Clinical Oncology</i> , 2015, 33, 1061-1061.	0.8	1
149	Adjuvant denosumab in breast cancer: Results from 3,425 postmenopausal patients of the ABCSG-18 trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 504-504.	0.8	6
150	Influence of immunohistological detection of intratumoral urokinase-type plasminogen activator (uPA) on disease outcome in endocrine-treated postmenopausal patients with hormone receptor-positive early breast cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 551-551.	0.8	1
151	Phase II study on the efficacy and safety of lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu: Positive advanced breast cancer (CECOG LaVie Trial).. <i>Journal of Clinical Oncology</i> , 2015, 33, e11603-e11603.	0.8	0
152	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>PLoS Genetics</i> , 2014, 10, e1004256.	1.5	47
153	Antiestrogenic effects of the fetal estrogen estetrol in women with estrogen-receptor positive early breast cancer. <i>Carcinogenesis</i> , 2014, 35, 2447-2451.	1.3	21
154	Central European <i>BRCA2</i> mutation carriers: Birth cohort status correlates with onset of breast cancer. <i>Maturitas</i> , 2014, 77, 68-72.	1.0	14
155	Follicle stimulating hormone (FSH) as a surrogate parameter for the effectiveness of endocrine therapy with or without zoledronic acid in premenopausal patients with breast cancer: An analysis of the prospective ABCSG-12 trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 577-577.	0.8	4
156	COX2, p16, and Ki67 expression in DCIS, microinvasive and early invasive breast carcinoma with extensive intraductal component.. <i>Journal of Clinical Oncology</i> , 2014, 32, e11519-e11519.	0.8	0
157	Effect of reproductive factors and lifestyle on the onset of breast cancer in female <i>BRCA 1</i> and <i>2</i> mutation carriers.. <i>Journal of Clinical Oncology</i> , 2014, 32, 1545-1545.	0.8	0
158	Quality of life in subjects who are at high risk for hereditary breast and/or ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, e12501-e12501.	0.8	0
159	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 371-384.	9.4	493
160	Cytosine 5-Hydroxymethylation of the LZTS1 Gene Is Reduced in Breast Cancer. <i>Translational Oncology</i> , 2013, 6, 715-IN27.	1.7	26
161	Genome-Wide Association Study in <i>BRCA1</i> Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. <i>PLoS Genetics</i> , 2013, 9, e1003212.	1.5	244
162	The impact of estrogen depletion by aromatase inhibitors on adiponectin serum levels in postmenopausal patients with breast cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, e11601-e11601.	0.8	3

#	ARTICLE	IF	CITATIONS
163	Response Prediction to Neoadjuvant Chemotherapy: Comparison between Pre-Therapeutic Gene Expression Profiles and In Vitro Chemosensitivity Assay. PLoS ONE, 2013, 8, e66573.	1.1	7
164	Elevated CSF-1 serum concentrations to predict lymph node metastasis and overall survival in women with early breast cancer.. Journal of Clinical Oncology, 2013, 31, 11032-11032.	0.8	0
165	Modern Risk Assessment for Individualizing Treatment Concepts in Early-stage Breast Cancer. Reviews in Obstetrics and Gynecology, 2013, 6, 165-73.	0.7	3
166	Pathology of Breast and Ovarian Cancers among <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: Results from the Consortium of Investigators of Modifiers of <i>BRCA1/2</i> (CIMBA). Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 134-147.	1.1	513
167	Estrogen receptor alpha (<i>ESR1</i>) gene amplification status and clinical outcome in tamoxifen-treated postmenopausal patients with endocrine-responsive early breast cancer: An analysis of the prospective ABCSG-6 trial.. Journal of Clinical Oncology, 2012, 30, 10501-10501.	0.8	3
168	Correlation of breast cancer risk in European <i>BRCA2</i> mutation carriers with birth cohort.. Journal of Clinical Oncology, 2012, 30, 1537-1537.	0.8	0
169	Impact of body mass index (BMI) on the efficacy of zoledronic acid in premenopausal patients with hormone receptor positive breast cancer: An analysis of the ABCSG-12 trial.. Journal of Clinical Oncology, 2012, 30, 514-514.	0.8	0
170	Are ulcerated breast cancers biologically more aggressive compared to their non-ulcerated counterparts?. Journal of Clinical Oncology, 2012, 30, 21-21.	0.8	0
171	Incomplete surgical resection of ductal carcinomas in situ results in activation of <i>ERBB2</i> in residual breast cancer cells. Endocrine-Related Cancer, 2009, 16, 73-83.	1.6	4
172	Differential gene expression profile in breast cancer-derived stromal fibroblasts. Breast Cancer Research and Treatment, 2008, 110, 273-281.	1.1	64
173	Climacteric Complaints after Breast Cancer – Is HRT an Option?. Breast Care, 2008, 3, 9-9.	0.8	1
174	Neoadjuvant Endocrine Therapy in Breast Cancer. Breast Care, 2008, 3, 303-308.	0.8	1